Low Christopher, Toye Warren, Phung Peter, Huston Christopher
GenesisCare Radiation Oncology Centre, Berwick, VIC, Australia.
North West Cancer Centre, North West Regional Hospital, Burnie, TAS, Australia.
J Med Phys. 2018 Apr-Jun;43(2):112-118. doi: 10.4103/jmp.JMP_138_17.
A retrospective study was performed to explore the use of dose volume histogram (DVH) metrics in a patient-specific quality assurance protocol for volumetric modulated arc therapy (VMAT). Fourteen head and neck (HN) and ten brain patients treated with VMAT at the Launceston General Hospital were retrospectively analyzed using the new protocol to identify cases where patient dose errors exceed the established action levels that were not originally detected by either point dose and/or gamma index methods. The Sun Nuclear 3DVH software was used to estimate the dose delivered to the patient volume in terms of DVH dose errors. Thus, three different pretreatment verification methods were used to assess if a plan was considered acceptable. In two particular cases, the dose difference determined with point dose was above the established threshold, although it was found that this was due to the placement of the chamber in the phantom. In all cases, 3DVH confirmed that the dose delivered to target volumes (planning target volume - D) and to relevant organs at risk was within prescribed dose tolerances. This study has demonstrated the integration of DVH metrics into a VMAT PSQA protocol to provide clinically meaningful results that complement point dose and gamma index measurements. 3DVH should be regarded as an investigative tool that may be useful in diagnosing the cause of failed plans since it allows dose errors to be related to the patient anatomy.
开展了一项回顾性研究,以探讨剂量体积直方图(DVH)指标在容积调强弧形放疗(VMAT)患者特异性质量保证方案中的应用。使用新方案对朗塞斯顿综合医院接受VMAT治疗的14例头颈部(HN)患者和10例脑部患者进行回顾性分析,以确定患者剂量误差超过既定行动水平且最初未被点剂量和/或伽马指数方法检测到的病例。使用Sun Nuclear 3DVH软件根据DVH剂量误差估算给予患者体积的剂量。因此,使用三种不同的治疗前验证方法来评估计划是否被认为可接受。在两个特定案例中,用点剂量确定的剂量差异高于既定阈值,不过发现这是由于电离室在模体中的放置所致。在所有案例中,3DVH证实给予靶体积(计划靶体积 - D)和相关危及器官的剂量在规定的剂量公差范围内。本研究证明将DVH指标整合到VMAT患者特异性质量保证方案中可提供具有临床意义的结果,补充点剂量和伽马指数测量。3DVH应被视为一种有助于诊断计划失败原因的调查工具,因为它可使剂量误差与患者解剖结构相关联。